Jeffrey Hung
Stock Analyst at Morgan Stanley
(4.22)
# 495
Out of 5,113 analysts
237
Total ratings
52.08%
Success rate
15.05%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey Hung
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CTNM Contineum Therapeutics | Downgrades: Equal-Weight | $23 → $14 | $14.09 | -0.64% | 5 | Jan 8, 2026 | |
| NBIX Neurocrine Biosciences | Downgrades: Equal-Weight | $173 → $175 | $133.89 | +30.70% | 32 | Jan 8, 2026 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Overweight | $77 → $80 | $52.97 | +51.04% | 4 | Jan 6, 2026 | |
| CYTK Cytokinetics | Maintains: Overweight | $65 → $71 | $64.01 | +10.92% | 14 | Dec 23, 2025 | |
| BIOA BioAge Labs | Upgrades: Equal-Weight | $5 → $12 | $19.60 | -38.78% | 3 | Dec 8, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $185 → $205 | $167.85 | +22.13% | 12 | Nov 17, 2025 | |
| ENGN enGene Holdings | Maintains: Overweight | $18 → $19 | $11.11 | +71.02% | 5 | Nov 12, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $122 → $129 | $105.53 | +22.24% | 14 | Oct 16, 2025 | |
| CGON CG Oncology | Maintains: Overweight | $56 → $79 | $55.10 | +43.38% | 5 | Sep 17, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $76 → $71 | $75.49 | -5.95% | 13 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $28 | $12.34 | +126.90% | 7 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $4 → $2 | $10.50 | -80.95% | 4 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $13 | $7.07 | +83.88% | 6 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $102 → $108 | $14.29 | +655.77% | 5 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $55 | $24.62 | +123.40% | 9 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $24 | $26.20 | -8.40% | 25 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $85 | $82.21 | +3.39% | 6 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $27 | $25.99 | +3.89% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $6.00 | +483.33% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $10 → $4 | $2.12 | +88.68% | 10 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $1 → $4 | $2.03 | +97.04% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $14 | $5.23 | +167.69% | 3 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $5 | $3.59 | +39.28% | 1 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $3 | $3.42 | -12.28% | 8 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $14 | $2.65 | +428.30% | 7 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $10 | $1.29 | +677.00% | 3 | Jan 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $23 → $22 | $43.74 | -49.70% | 10 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $146 → $149 | $12.67 | +1,072.06% | 2 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $100 → $60 | $0.83 | +7,137.64% | 5 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $6 | $3.94 | +52.28% | 9 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $696 → $648 | $11.12 | +5,727.34% | 6 | May 8, 2020 |
Contineum Therapeutics
Jan 8, 2026
Downgrades: Equal-Weight
Price Target: $23 → $14
Current: $14.09
Upside: -0.64%
Neurocrine Biosciences
Jan 8, 2026
Downgrades: Equal-Weight
Price Target: $173 → $175
Current: $133.89
Upside: +30.70%
Crinetics Pharmaceuticals
Jan 6, 2026
Maintains: Overweight
Price Target: $77 → $80
Current: $52.97
Upside: +51.04%
Cytokinetics
Dec 23, 2025
Maintains: Overweight
Price Target: $65 → $71
Current: $64.01
Upside: +10.92%
BioAge Labs
Dec 8, 2025
Upgrades: Equal-Weight
Price Target: $5 → $12
Current: $19.60
Upside: -38.78%
Jazz Pharmaceuticals
Nov 17, 2025
Maintains: Overweight
Price Target: $185 → $205
Current: $167.85
Upside: +22.13%
enGene Holdings
Nov 12, 2025
Maintains: Overweight
Price Target: $18 → $19
Current: $11.11
Upside: +71.02%
Rhythm Pharmaceuticals
Oct 16, 2025
Maintains: Overweight
Price Target: $122 → $129
Current: $105.53
Upside: +22.24%
CG Oncology
Sep 17, 2025
Maintains: Overweight
Price Target: $56 → $79
Current: $55.10
Upside: +43.38%
PTC Therapeutics
Aug 20, 2025
Maintains: Overweight
Price Target: $76 → $71
Current: $75.49
Upside: -5.95%
Aug 18, 2025
Maintains: Overweight
Price Target: $35 → $28
Current: $12.34
Upside: +126.90%
Aug 18, 2025
Downgrades: Equal-Weight
Price Target: $4 → $2
Current: $10.50
Upside: -80.95%
Aug 12, 2025
Maintains: Equal-Weight
Price Target: $17 → $13
Current: $7.07
Upside: +83.88%
Jul 17, 2025
Upgrades: Overweight
Price Target: $102 → $108
Current: $14.29
Upside: +655.77%
Jul 14, 2025
Maintains: Overweight
Price Target: $65 → $55
Current: $24.62
Upside: +123.40%
May 20, 2025
Maintains: Equal-Weight
Price Target: $20 → $24
Current: $26.20
Upside: -8.40%
Mar 7, 2025
Assumes: Overweight
Price Target: $85
Current: $82.21
Upside: +3.39%
Mar 7, 2025
Assumes: Overweight
Price Target: $27
Current: $25.99
Upside: +3.89%
Jul 26, 2024
Initiates: Overweight
Price Target: $35
Current: $6.00
Upside: +483.33%
Dec 19, 2023
Downgrades: Underweight
Price Target: $10 → $4
Current: $2.12
Upside: +88.68%
Dec 19, 2023
Upgrades: Equal-Weight
Price Target: $1 → $4
Current: $2.03
Upside: +97.04%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $14
Current: $5.23
Upside: +167.69%
Jul 11, 2023
Reiterates: Equal-Weight
Price Target: $5
Current: $3.59
Upside: +39.28%
Mar 20, 2023
Maintains: Equal-Weight
Price Target: $9 → $3
Current: $3.42
Upside: -12.28%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $15 → $14
Current: $2.65
Upside: +428.30%
Jan 30, 2023
Downgrades: Underweight
Price Target: $50 → $10
Current: $1.29
Upside: +677.00%
Nov 2, 2022
Maintains: Equal-Weight
Price Target: $23 → $22
Current: $43.74
Upside: -49.70%
May 11, 2022
Maintains: Equal-Weight
Price Target: $146 → $149
Current: $12.67
Upside: +1,072.06%
Aug 13, 2021
Downgrades: Underweight
Price Target: $100 → $60
Current: $0.83
Upside: +7,137.64%
Apr 19, 2021
Maintains: Equal-Weight
Price Target: $7 → $6
Current: $3.94
Upside: +52.28%
May 8, 2020
Maintains: Overweight
Price Target: $696 → $648
Current: $11.12
Upside: +5,727.34%